ABSTRACT
Purpose To investigate the expression of LI-cadherin in advanced gastric cancer and its effect and mecha-nism on human gastric cancer cell line MKN28. Methods Im-munohistochemical staining was performed on advanced gastric cancer to examine the LI-cadherin protein expression. CCK8, colony formation assay, transwell assay, flow cytometry were used to detect the changes in the biological behavior of MKN28 cells after LI-cadherin gene interference. Dual-luciferase report-er assay and Western blot were used to detect the activity of the NF-κB after the interference of LI-cadherin gene. Results LI-cadherin in chronic gastritis was negative, in well- and moder-ately-differentiated advanced gastric cancer was significantly in-creased, in poorly-differentiated was decreased. Cell prolifera-tion, colony formation, and invation ability were inhibited in the group of knockdown expression of LI-cadherin ( P ＜ 0. 05 ). Flow cytometry results showed that knockdown expression of LI-cadherin resulted in a significant increase in the proportion of cells in G1 phase, while the proportion of cells in S phase was significantly lower ( P ＜0. 05 ). Knockdown expression of LI-cadherin resulted in the decreased activation of NF-κB and re-stricted its translation. Conclusion LI-cadherin in well- and moderately-differentiated advanced gastric cancer is significantly increased. Knockdown of LI-cadherin can strongly decrease the malignant biological characteristics of human gastric cancer cell line MKN28. Its mechanism may be associated with the NF-κB pathway.
ABSTRACT
<p><b>OBJECTIVE</b>To observe the effect of combined therapy with Xuezhikang Capsule (XZK) and Valsartan on left ventricular hypertrophy (LVH) and heart rate turbulence (HRT) in hypertensive patients.</p><p><b>METHODS</b>Ninety primary hypertensive patients with LVH were randomly assigned to three groups. Basic treatment, including aspirin, beta-blockers, calcium antagonists, etc. were administered to all patients. Additionally, Valsartan (VS, 80 mg once a day) was given to the 30 patients in the VS group. Valsartan (in the same dosage) and XZK (600 mg, twice a day) were given to the 32 patients in the Chinese medicine (CM) group, while none was given to the 28 patients in the control group. The therapeutic course lasted for 24 months. Changes in left ventricular mass index (LVMI) measured by cardiac ultrasonic indices, HRT parameters, including the original heart rate (TO) and slope coeffificient (TS), systolic and diastolic blood pressures (SBP and DBP), as well as blood cholesterol level (TC) were measured before and after treatment.</p><p><b>RESULTS</b>After treatment, TO and LVMI were lowered, while TS increased in both the VS group and the CM group (P<0.01), but changed insignificantly in the control group. Significant differences between the CM group and the control group were shown in terms of TO, LVMI, SBP, DBP and TS (P<0.01); and between the CM group and the VS group in terms of TO, LVMI and TS (P<0.01). Moreover, HRT parameters showed an evident correlation with LVMI (r=0.519-0.635, P<0.01).</p><p><b>CONCLUSION</b>Combined therapy with XZK and Valsartan can improve hypertensive LVH and HRT parameters, and lessen the damage on the autonomous nervous system.</p>